Grape King Bio Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grape King Bio Ltd with three other
companies in this sector in Taiwan:
Yungshin Global Holding Corp
sales of 6.62 billion Taiwanese Dollars [US$221.86 million]
of which 73%
was Taiwan District),
China Chemical and Pharmaceutical Company Limited
(6.24 billion Taiwanese Dollars [US$209.20 million]
of which 72%
was Taiwan), and
Lotus Pharmaceutical Co.,Ltd.
(6.42 billion Taiwanese Dollars [US$215.20 million]
of which 90%
was Western Medicine Manufacture).
During the year ended December of 2017, sales at
Grape King Bio Ltd were 9.39 billion Taiwanese Dollars (US$314.50 million).
increase of 2.2%
versus 2016, when the company's sales were 9.19 billion Taiwanese Dollars.
This was the fifth consecutive year of sales increases at Grape King Bio Ltd
(and since 2012, sales have increased a total of 104%).
Sales of Oem Department saw an increase
that was more than double the company's growth rate: sales were up
50.8% in 2017, from
689.94 million Taiwanese Dollars to 1.04 billion Taiwanese Dollars.
Not all segments of Grape King Bio Ltd experienced an increase in sales in 2017:
sales of Distribution Sector fell 8.7% to 297.46 million Taiwanese Dollars.
(However, this segment's sales were only a very small portion of the company's overall sales).
Grape King Bio Ltd also experienced decreases in sales in
Direct Sales (down 1.5% to 8.05 billion Taiwanese Dollars)